MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

MDT

97.25

+1.88%↑

VEEV

300.62

+4.11%↑

139.72

-0.04%↓

HQY

90.34

-0.32%↓

PHR.US

23.41

+5.4%↑

Home・Aandelen Lijst・Collegium Pharmaceutical Inc

C
Collegium Pharmaceutical Inc

Open

SectorGezondheidszorg

35.03 1.33

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

33.85

Max

34.96

Belangrijke statistieken
By Trading Economics
Inkomsten	9.6M 12M
Verkoop	10M 188M
K/W Sectorgemiddelde	32.613 35.739
Winstmarge	6.374
Werknemers	357
EBITDA	14M 94M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+21.13% upside

Dividenden
By Dow Jones
Volgende Winsten	6 nov 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	90M 1.1B
Vorige openingsprijs	33.7
Vorige sluitingsprijs	35.03

Nieuwssentiment

By Acuity

78%

22%

345 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

27.09 / 27.6 Steun & Weerstand

Collegium Pharmaceutical Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 okt 2025, 23:30 UTC

Populaire aandelen

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2 okt 2025, 21:21 UTC

Winsten

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3 okt 2025, 00:00 UTC

Acquisities, Fusies, Overnames

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2 okt 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2 okt 2025, 23:39 UTC

Marktinformatie

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2 okt 2025, 23:29 UTC

Acquisities, Fusies, Overnames

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2 okt 2025, 23:00 UTC

Marktinformatie

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Scales's JV Buyout Lauded by Bull -- Market Talk

2 okt 2025, 22:54 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Forex and Fixed Income Roundup: Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2 okt 2025, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

2 okt 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2 okt 2025, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Energy & Utilities Roundup: Market Talk

2 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 okt 2025, 20:49 UTC

Acquisities, Fusies, Overnames

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2 okt 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2 okt 2025, 19:20 UTC

Marktinformatie

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2 okt 2025, 19:10 UTC

Marktinformatie

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2 okt 2025, 19:04 UTC

Marktinformatie

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2 okt 2025, 18:46 UTC

Acquisities, Fusies, Overnames

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2 okt 2025, 18:45 UTC

Acquisities, Fusies, Overnames

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2 okt 2025, 18:44 UTC

Acquisities, Fusies, Overnames

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2 okt 2025, 18:43 UTC

Acquisities, Fusies, Overnames

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Peer Vergelijking

Prijswijziging

Collegium Pharmaceutical Inc Prognose

Koersdoel

By TipRanks

21.13% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 42.6 USD 21.13%

Hoogste 46 USD

Laagste 38 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Collegium Pharmaceutical Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Collegium Pharmaceutical Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.09 / 27.6Steun & Weerstand

Bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

345 / 371 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.